NCT05634174 is a Phase 1 clinical trial of Mirabegron in Obesity, Prediabetes, sponsored by University of California, San Diego.

Who is sponsoring NCT05634174?

NCT05634174 is sponsored by University of California, San Diego.

What drugs are being tested in NCT05634174?

Interventions in NCT05634174: Mirabegron.

What condition does NCT05634174 study?

NCT05634174 studies Obesity, Prediabetes.

Is NCT05634174 still recruiting?

NCT05634174 is currently active, enrolled. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT05634174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ADRB3 Signaling Pathway in Human Adipose Tissue

Active, enrolled Phase 1 Last updated 15 October 2024

What this trial tests

Phase 1 trial testing Mirabegron in Obesity, Prediabetes in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 August 2023

Primary endpoint
30 September 2025

31 December 2025

Quick facts

Lead sponsor	University of California, San Diego
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	1 August 2023
Primary completion	30 September 2025
Estimated completion	31 December 2025
Sites	1 location across United States

Drugs / interventions tested

Mirabegron (MIRABEGRON) — full drug profile →

Conditions studied

Obesity, Prediabetes — all drugs for Obesity, Prediabetes →

Sponsor

University of California, San Diego

Who can join

Adults 18 to 70, any sex, with Obesity, Prediabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine the gene expression of the adrenergic Beta-3 receptor (ADRB3) regulation in human subcutaneous adipose tissue before and after treatment with mirabegron, an ADRB3 agonist. Gene expression will be compared across two groups, lean and obese participants. There will be a total of three study visits: Screening/Eligibility, Pre-Dose Adipose Tissue Biopsy and Post-Dose Adipose Tissue Biopsy. Participants will be given a single dose of 100mg oral mirabegron on the day of the Post-Dose Adipose Tissue Biopsy.The trial design is a single-center, phase 1, open-label, exploratory study to examine the adipocyte gene expression in adults treated with 1 dose of 100mg oral mirabegron.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Mirabegron

Trials testing the same drug.

NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
NCT07310797 — Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion · Phase 4 · not yet recruiting
NCT06534762 — Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study · Phase 2 · recruiting
NCT06551246 — Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) · Phase 3 · recruiting
NCT06465576 — Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) · Phase 4 · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05634174 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05634174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing